Neuroscience biotech Cerevance launched with mm Series A, including investment from Takeda

Jan 2017 Executive Summary Neuroscience start-up Cerevance Inc. (focused on therapeutics for neurological and psychiatric disorders) was launched with a $36mm Series A round, including a $21.5mm investment from Takeda Pharmaceutical and Lightstone Ventures, which both contributed a member to the new company’s board. Already a Strategic Transactions subscriber? You have access to the full deal record through your subscription View on strategic transactions Want to become a subscriber? Subscribers get more deal details, updates, deal financials and deal products Learn more Questions? Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com


Link to Full Article: Neuroscience biotech Cerevance launched with mm Series A, including investment from Takeda